Found: 60
Select item for more details and to access through your institution.
Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in People With Treated Human Immunodeficiency Virus.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 3, p. 1, doi. 10.1093/ofid/ofad106
- By:
- Publication type:
- Article
Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus.
- Published in:
- Open Forum Infectious Diseases, 2021, v. 8, n. 12, p. 1, doi. 10.1093/ofid/ofab537
- By:
- Publication type:
- Article
Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, n. 2, p. N.PAG, doi. 10.1093/ofid/ofz022
- By:
- Publication type:
- Article
Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia.
- Published in:
- Open Forum Infectious Diseases, 2015, v. 2, n. 3, p. 1, doi. 10.1093/ofid/ofv085
- By:
- Publication type:
- Article
Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics.
- Published in:
- Open Forum Infectious Diseases, 2015, v. 2, n. 1, p. 1, doi. 10.1093/ofid/ofu117
- By:
- Publication type:
- Article
Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.924718
- By:
- Publication type:
- Article
A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease.
- Published in:
- Journal of Infectious Diseases, 2003, v. 188, n. 5, p. 625
- By:
- Publication type:
- Article
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Clinical and Genetic Determinants of Plasma Nevirapine Exposure Following an Intrapartum Dose to Prevent Mother-to-Child HIV Transmission.
- Published in:
- Journal of Infectious Diseases, 2013, v. 208, n. 4, p. 662, doi. 10.1093/infdis/jit223
- By:
- Publication type:
- Article
Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure.
- Published in:
- Journal of Infectious Diseases, 2013, v. 207, n. 6, p. 893, doi. 10.1093/infdis/jis925
- By:
- Publication type:
- Article
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202.
- Published in:
- Journal of Infectious Diseases, 2013, v. 207, n. 3, p. 420, doi. 10.1093/infdis/jis690
- By:
- Publication type:
- Article
Highly Active Antiretroviral Therapy and Adverse Birth Outcomes Among HIV-Infected Women in Botswana.
- Published in:
- Journal of Infectious Diseases, 2012, v. 206, n. 11, p. 1695, doi. 10.1093/infdis/jis553
- By:
- Publication type:
- Article
Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study.
- Published in:
- Journal of Infectious Diseases, 2010, v. 202, n. 5, p. 717, doi. 10.1086/655470
- By:
- Publication type:
- Article
Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure.
- Published in:
- Journal of Infectious Diseases, 2010, v. 201, n. 5, p. 662, doi. 10.1086/650543
- By:
- Publication type:
- Article
Efavirenz-Based Regimens in Treatment-Naive Patients with a Range of Pretreatment HIV-1 RNA Levels and CD4 Cell Counts.
- Published in:
- Journal of Infectious Diseases, 2008, v. 197, n. 7, p. 1006, doi. 10.1086/529208
- By:
- Publication type:
- Article
Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects.
- Published in:
- Journal of Infectious Diseases, 2008, v. 197, n. 6, p. 867, doi. 10.1086/528802
- By:
- Publication type:
- Article
Plasma HIV-1 RNA Dynamics in Antiretroviral-Naive Subjects Receiving either Triple-Nucleoside or Efavirenz-Containing Regimens: ACTG A5166s.
- Published in:
- Journal of Infectious Diseases, 2007, v. 195, n. 8, p. 1169, doi. 10.1086/512619
- By:
- Publication type:
- Article
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 Infection.
- Published in:
- JAMA: Journal of the American Medical Association, 2006, v. 296, n. 7, p. 769, doi. 10.1001/jama.296.7.769
- By:
- Publication type:
- Article
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial.
- Published in:
- Clinical Infectious Diseases, 2021, v. 73, n. 11, p. 2009, doi. 10.1093/cid/ciab552
- By:
- Publication type:
- Article
A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.
- Published in:
- Clinical Infectious Diseases, 2019, v. 69, n. 7, p. 1165, doi. 10.1093/cid/ciy1051
- By:
- Publication type:
- Article
Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.
- Published in:
- Clinical Infectious Diseases, 2019, v. 68, n. 11, p. 1877, doi. 10.1093/cid/ciy781
- By:
- Publication type:
- Article
Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial.
- Published in:
- Clinical Infectious Diseases, 2019, v. 68, n. 6, p. 1044, doi. 10.1093/cid/ciy764
- By:
- Publication type:
- Article
Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257.
- Published in:
- Clinical Infectious Diseases, 2016, v. 62, n. 12, p. 1842, doi. 10.1093/cid/civ193
- By:
- Publication type:
- Article
Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.
- Published in:
- Clinical Infectious Diseases, 2016, v. 62, n. 7, p. 853, doi. 10.1093/cid/ciw017
- By:
- Publication type:
- Article
Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, n. 4, p. 651, doi. 10.1093/cid/civ327
- By:
- Publication type:
- Article
Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257.
- Published in:
- Clinical Infectious Diseases, 2015, v. 60, n. 12, p. 1842, doi. 10.1093/cid/civ193
- By:
- Publication type:
- Article
Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.
- Published in:
- Clinical Infectious Diseases, 2015, v. 60, n. 10, p. 1552, doi. 10.1093/cid/civ109
- By:
- Publication type:
- Article
Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis.
- Published in:
- Clinical Infectious Diseases, 2013, v. 57, n. 11, p. 1607, doi. 10.1093/cid/cit595
- By:
- Publication type:
- Article
Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial.
- Published in:
- Journal of the American Heart Association, 2024, v. 13, n. 7, p. 1, doi. 10.1161/JAHA.123.033413
- By:
- Publication type:
- Article
Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort.
- Published in:
- Clinical Infectious Diseases, 2023, v. 77, n. 12, p. 1676, doi. 10.1093/cid/ciad419
- By:
- Publication type:
- Article
Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE).
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 11, p. 2010, doi. 10.1093/cid/ciad107
- By:
- Publication type:
- Article
Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV).
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 3, p. e613, doi. 10.1093/cid/ciac662
- By:
- Publication type:
- Article
Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk.
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 7, p. 1154, doi. 10.1093/cid/ciac098
- By:
- Publication type:
- Article
CHANGES IN BODY MASS INDEX WITH INTEGRASE INHIBITOR USE IN REPRIEVE.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 279
- By:
- Publication type:
- Article
IMPACT OF COVID-19 AND HOST FACTORS ON THE HUMORAL IMMUNE REPERTOIRE IN TREATED HIV.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 138
- By:
- Publication type:
- Article
BASELINE AND TEMPORAL DIFFERENCES IN PROTEOMICS FOLLOWING SARS-CoV-2 INFECTION IN PWH.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 110
- By:
- Publication type:
- Article
Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis.
- Published in:
- JAMA: Journal of the American Medical Association, 2011, v. 305, n. 13, p. 1327, doi. 10.1001/jama.2011.375
- By:
- Publication type:
- Article
Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation.
- Published in:
- Annals of Internal Medicine, 2015, v. 162, n. 12, p. 815, doi. 10.7326/M14-1409
- By:
- Publication type:
- Article
Three Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1.
- Published in:
- Annals of Internal Medicine, 2015, v. 162, n. 6, p. 461, doi. 10.7326/L15-5066-3
- By:
- Publication type:
- Article
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1.
- Published in:
- Annals of Internal Medicine, 2014, v. 161, n. 7, p. 461, doi. 10.7326/M14-1084
- By:
- Publication type:
- Article
COVID-19 Vaccination Rates in a Global HIV Cohort.
- Published in:
- 2022
- By:
- Publication type:
- Journal Article
Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.
- Published in:
- 2020
- By:
- Publication type:
- journal article